NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) is a clinical-stage biopharmaceutical company with zero product revenue, zero inventory, and no tangible asset base of consequence. The liquidation value is deeply negative. MFFAIS pegs the latest CLV/LLV/OLV at negative $20.95 million as of the March 31, 2026 period end, and the filing confirms this assessment directionally. Cash at March 31, 2026 was $138,601 — effectively zero recovery from the asset side. The company reports an accumulated deficit of $121.6 million versus $112.8 million at December 31, 2025, a $8.8 million deterioration in a single quarter. On the liability side, the most material items from the narrative are: (1) litigation settlement payable to Orient EuroPharma (OEP) of $4,304,110 as of March 31, 2026, unpaid as of the filing date despite being triggered by the March 2025 IPO listing — this is a hard cash obligation accruing interest with no payment timeline disclosed; (2) accrued restricted stock tax withholding obligations of $6,077,719, representing withheld shares covering recipients' tax liabilities that have not been remitted to taxing authorities — the company describes this as actively evaluating remediation, and $644,601 of penalties and interest were recognized in Q1 2026 alone for this failure; (3) a $10.0 million related-party line of credit with HCWG (undrawn as of March 31, 2026) with $1.03 million in unamortized debt issuance costs on balance sheet. The filing does not separately XBRL-tag any balance sheet line items — TAG_CONTEXT is empty — so all liability and asset figures cited are drawn from narrative disclosures and cannot be cross-referenced to tagged data. The company carries going concern language explicitly, with management concluding substantial doubt exists about continuation for at least one year. Operating cash burn was $7.0 million in Q1 2026, financed almost entirely by PIPE equity issuances ($13.1 million gross proceeds from three Securities Purchase Agreements in Q1 2026, with a fourth closing April 20, 2026 for $2.0 million). Post-period, the board approved acceleration of 727,606 unvested restricted shares on April 30, 2026, triggering approximately $4.3 million in additional stock-based compensation and further payroll tax withholding obligations. A $300 million S-3 shelf and a $75 million ATM facility with BTIG/AGP were declared effective April 9-10, 2026, providing structural capital access but with no proceeds as of the filing date. Under a liquidation scenario, recoverable assets are negligible: cash of $139K (100% recovery), a grant receivable of $118K (high-quality NIH receivable, near 100% recovery), and a patent acquired for $500K in October 2025 that would realistically fetch nominal value at forced sale (0% applied under the lens). Against these, face-value liabilities include the $4.3 million OEP settlement, $6.1 million tax withholding accrual, ongoing accrued advisory fees to related party AFH at $1.36 million per quarter, accrued legal/professional expenses, and ASC 842 lease obligations. The filing discloses material weaknesses in internal controls — segregation of duties, IT access, related-party transaction controls — that have not been remediated as of March 31, 2026, adding execution risk to any reported figures. Filing discusses the OEP litigation settlement payable, accrued restricted stock tax withholding obligations, unamortized debt issuance costs, operating lease ROU asset, intangible asset amortization, and derivative liability in MD&A and footnotes but does not separately tag any of these in XBRL, as TAG_CONTEXT is empty. All quantitative references in this analysis are drawn exclusively from narrative disclosures.
▼ Community Notes